March 14, 2023 (revised) Matthew Winton, PhD Dear Matthew:Inozyme Pharma, Inc. • May 9th, 2023 • Pharmaceutical preparations • Massachusetts
On behalf of Inozyme Pharma Inc. (the “Company”), I am pleased to offer you employment with the Company. The purpose of this letter (the “Letter Agreement”) is to summarize the terms of your employment with the Company, should you accept our offer:
Inozyme Pharma, Inc. RESTRICTED STOCK UNIT AGREEMENT Granted under 2023 Inducement Stock Incentive PlanRestricted Stock Unit Agreement • May 9th, 2023 • Inozyme Pharma, Inc. • Pharmaceutical preparations • Delaware
This grant of RSUs satisfies in full all commitments that the Company has to the Participant with respect to the issuance of stock, stock options or other equity securities.
Consulting AgreementConsulting Agreement • May 9th, 2023 • Inozyme Pharma, Inc. • Pharmaceutical preparations • Massachusetts
This Consulting Agreement (the “Agreement”), effective as of the Effective Date (as defined herein), is entered into between Inozyme Pharma, Inc. (the “Company”) and Axel Bolte (the “Consultant”).
Inozyme Pharma, Inc. 321 Summer Street Suite 400 Boston, Massachusetts 02210Letter Agreement • May 9th, 2023 • Inozyme Pharma, Inc. • Pharmaceutical preparations • Massachusetts
On behalf of Inozyme Pharma Inc. (the “Company”), I am pleased to offer you employment with the Company. The purpose of this letter (the “Letter Agreement”) is to summarize the terms of your employment with the Company, should you accept our offer:
Inozyme Pharma, Inc. 321 Summer Street Suite 400 Boston, Massachusetts 02210Inozyme Pharma, Inc. • May 9th, 2023 • Pharmaceutical preparations
As we have discussed, you are retiring and resigning from employment with Inozyme Pharma Switzerland GmbH (the “Company”), effective April 30, 2023 (the “Separation Date”). By countersigning and returning this letter agreement, you will be entering into a binding agreement with the Company and will be agreeing to the terms and conditions set forth in the numbered paragraphs below, including the release of claims set forth in paragraph 3. The severance benefits described in paragraph 2 below will be subject to you adhering to this letter agreement and returning a signed waiver in the form of Annex 1 on but not earlier than May 31, 2023 and not revoking your agreement to the waiver in Annex 1 (as described below) during the seven (7) day period after you have signed or timely revoking paragraph 4(b) below, in either case by notifying me in writing.
Inozyme Pharma, Inc. NONSTATUTORY STOCK OPTION AGREEMENT Granted under 2023 Inducement Stock Incentive PlanNonstatutory Stock Option Agreement • May 9th, 2023 • Inozyme Pharma, Inc. • Pharmaceutical preparations
This option satisfies in full all commitments that the Company has to the Participant with respect to the issuance of stock, stock options or other equity securities.
